Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$12.6 million.

  • Oncology Institute's Cash from Operations fell 164212.45% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.8 million, marking a year-over-year increase of 3118.99%. This contributed to the annual value of -$26.5 million for FY2024, which is 2692.28% up from last year.
  • Oncology Institute's Cash from Operations amounted to -$12.6 million in Q3 2025, which was down 164212.45% from -$10.2 million recorded in Q2 2025.
  • Oncology Institute's Cash from Operations' 5-year high stood at $4.0 million during Q4 2024, with a 5-year trough of -$23.3 million in Q4 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$10.2 million (2025), whereas its average is -$9.8 million.
  • As far as peak fluctuations go, Oncology Institute's Cash from Operations soared by 171391.3% in 2021, and later plummeted by 375969.83% in 2022.
  • Quarter analysis of 5 years shows Oncology Institute's Cash from Operations stood at -$23.3 million in 2021, then surged by 40.02% to -$14.0 million in 2022, then skyrocketed by 72.19% to -$3.9 million in 2023, then soared by 202.75% to $4.0 million in 2024, then plummeted by 415.75% to -$12.6 million in 2025.
  • Its Cash from Operations was -$12.6 million in Q3 2025, compared to -$10.2 million in Q2 2025 and -$5.0 million in Q1 2025.